Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Fischer

Showing results (161-170 of 323) with videos related to

Pageof 33
Sort By:
Frontiers in Genetics|October 15, 2021
Haploinsufficiency of the Attention-Deficit/Hyperactivity Disorder Risk Gene <i>St3gal3</i> in Mice Causes Alterations in Cognition and Expression of Genes Involved in Myelination and SialylationOlga Rivero, Judit Alhama-Riba, Hsing-Ping Ku, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer Reports (Hoboken, N.J.)|July 28, 2022
Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastomaLara Riehl, Medhanie Mulaw, Katharina Kneer, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 11, 2022
Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma modelsJanina Fischer-Mertens, Felix Otte, Andrea Roderwieser, et al.
Cancer Research|March 10, 2011
CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cellsKai-Oliver Henrich, Tobias Bauer, Johannes Schulte, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Cancers|September 10, 2021
Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by <i>MYCN</i> AmplificationFrank Berthold, Angela Ernst, Sandra Ackermann, et al.
Microorganisms|September 28, 2021
What WGS Reveals about <i>Salmonella enterica</i> subsp. <i>enterica</i> in Wildlife in GermanyLaura Uelze, Angelina Bloch, Maria Borowiak, et al.
Iscience|June 30, 2026
Neuronal differentiation of neuroblastoma cell lines for neurological disease modelingClaudia Pommerenke, Vivien Hauer, Sonja Eberth, et al.
Journal of Translational Medicine|May 19, 2016
An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastomaDaniela Formicola, Giuseppe Petrosino, Vito Alessandro Lasorsa, et al.
Pageof 33

Showing results (161-170 of 323) with videos related to

Sort By:
Pageof 33
Frontiers in Genetics|October 15, 2021
Haploinsufficiency of the Attention-Deficit/Hyperactivity Disorder Risk Gene <i>St3gal3</i> in Mice Causes Alterations in Cognition and Expression of Genes Involved in Myelination and SialylationOlga Rivero, Judit Alhama-Riba, Hsing-Ping Ku, et al.
Cancer|December 29, 2015
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group projectDaria Thompson, Kieuhoa T Vo, Wendy B London, et al.
Cancer Reports (Hoboken, N.J.)|July 28, 2022
Targeted parallel DNA sequencing detects circulating tumor-associated variants of the mitochondrial and nuclear genomes in patients with neuroblastomaLara Riehl, Medhanie Mulaw, Katharina Kneer, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 11, 2022
Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma modelsJanina Fischer-Mertens, Felix Otte, Andrea Roderwieser, et al.
Cancer Research|March 10, 2011
CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cellsKai-Oliver Henrich, Tobias Bauer, Johannes Schulte, et al.
Pediatric Blood & Cancer|May 23, 2019
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectKevin Campbell, Derek Shyr, Rochelle Bagatell, et al.
Cancers|September 10, 2021
Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by <i>MYCN</i> AmplificationFrank Berthold, Angela Ernst, Sandra Ackermann, et al.
Microorganisms|September 28, 2021
What WGS Reveals about <i>Salmonella enterica</i> subsp. <i>enterica</i> in Wildlife in GermanyLaura Uelze, Angelina Bloch, Maria Borowiak, et al.
Iscience|June 30, 2026
Neuronal differentiation of neuroblastoma cell lines for neurological disease modelingClaudia Pommerenke, Vivien Hauer, Sonja Eberth, et al.
Journal of Translational Medicine|May 19, 2016
An 18 gene expression-based score classifier predicts the clinical outcome in stage 4 neuroblastomaDaniela Formicola, Giuseppe Petrosino, Vito Alessandro Lasorsa, et al.
Pageof 33